Abstract
The aim of this systematic review is to compare Chinese herbal medicine combined with Sorafenib in terms of efficacy and acceptability in the primary liver cancer to better inform clinical practice. To this end, the proposed systematic review will address the following question: Which is the best choice to reduce Efficacy and safety in Patients with primary liver cancer, Chinese herbal medicine combined with Sorafenib or Sorafenib.this systematic review and meta-analysis will evaluate the efficacy and Sorafenib combined with Chinese herbal medicine in the treatment of PLC. Information sources: We will search the following databases from inception up to September 8, 2021: PubMed, Web of Science, Embase, AMED, Cochrane Library, CNKI, VIP, CBM, and Wanfang. There will be no restrictions regarding publication date or language. We will apply a combination of medical keywords and words, including "Sorafenib", "Chinese herbal medicine" and "primary liver cancer". Additionally, we will manually search all reference lists from relevant systematic reviews to find other eligible studies.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
